suggested 30 % decrease in progression or deaths (PFS) (PE)
1) The addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab is safe and improved progression-free survival in patients with previously untreated metastatic colorectal cancer2) Pts with IS IC-high and/or TMB high pMMR mCRC seem to derive a survival benefit from adding atezo to FOLFOXIRI/bev as upfront treatment.
inconclusive 19 % decrease in progression or deaths (PFS) (PE)
The CheckMate 9X8 trial investigating first-line nivolumab plus SOC versus SOC in patients with mCRC did not meet its primary endpoint of PFS by BICR. Nivolumab plus SOC showed numerically higher PFS rates after 12 months, a higher response rate, and more durable responses compared with SOC alone, with acceptable safety
The investigational regimen did not improve the primary outcome for the intention-to-treat population but might benefit small subgroups of patients with previously untreated, metastatic microsatellite-stable colorectal cancer.
demonstrated 40 % decrease in progression or deaths (PFS) (PE)
this study demonstrated a doubling in progression-free survival (PFS) with pembrolizumab versus standard chemotherapy in patients with newly diagnosed MSI-H mCRC leading to FDA approval for pembrolizumab in first line treatment of patients with unresectable or metastatic MSI-H/dMMR CRC
Addition of Durvalumab plus Oleclumab to FOLFOX plus BEV (SoC) showed a moderate response increase without PFS benefit vs SoC alone. Safety was consistent with known safety profiles
delta: difference in rate or median (if available)
